Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 4/2016

01.12.2016 | short review

Therapy for EGFR tyrosine kinase inhibitor-resistant NSCLC with a focus on the T790M-resistant mutation

verfasst von: MD, Priv. Doz. August Zabernigg

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

The molecular characterisation of nonsquamous lung cancer has now become a standard procedure. In addition to the rare EML4-ALK and ROS-1 mutations, the detection of an epidermal growth factor receptor (EGFR) mutation has become a crucial factor in the selection of an optimal targeted therapy. Deletion of exon 19 and the L858R point mutation account for approximately 90 % of activating EGFR mutations and patients with these mutations are highly sensitive to treatment with EGFR tyrosine kinase inhibitors (EGFR TKIs). First-generation EGFR TKIs (gefitinib, erlotinib) reversibly inhibit the EGFR tyrosine kinase, while second-generation EGFR TKIs (afatinib, dacomitinib) are irreversible EGFR TKIs. However, despite an often excellent initial response to treatment with first- or second-generation EGFR TKIs, patients eventually develop drug resistance after approximately 9–12 months of treatment. T790M-targeting third-generation EGFR TKIs as osimertinib and rociletinib have shown high response rates of about 60 % in EGFR T790M-positive pretreated patients with a favourable toxicity profile. Unfortunately, patients eventually developed resistance to these drugs after approximately 10 months and the third-generation EGF R Cys797S mutation was recently reported to be a potential mechanism of resistance to third-EGFR TKIs.
Literatur
1.
Zurück zum Zitat Scagliotti G, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–51. CrossRef Scagliotti G, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–51. CrossRef
2.
Zurück zum Zitat Sandler A, Yi J, Dahlberg S, Kolb MM, Wang L, Hambleton J, Schiller J, et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol. 2010;5(9):1416–23. CrossRef Sandler A, Yi J, Dahlberg S, Kolb MM, Wang L, Hambleton J, Schiller J, et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol. 2010;5(9):1416–23. CrossRef
3.
Zurück zum Zitat Han S, Kim T, Hwang P, Jeong S, Kim J, Choi I, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2005;23(11):2493–501. CrossRef Han S, Kim T, Hwang P, Jeong S, Kim J, Choi I, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2005;23(11):2493–501. CrossRef
4.
Zurück zum Zitat Warth A, Endris V, Penzel R, Weichert W. Molekularpathologie des Lungenkarzinoms „State of the art“ 2014. Pathologe. 2014;35(6):565–73. CrossRef Warth A, Endris V, Penzel R, Weichert W. Molekularpathologie des Lungenkarzinoms „State of the art“ 2014. Pathologe. 2014;35(6):565–73. CrossRef
5.
Zurück zum Zitat Warth A, Endris V, Kriegsmann M, Stenzinger A, Penzel R, Pfarr N, Weichert W. Molekulardiagnostik des nichtkleinzelligen Lungenkarzinoms. Neue Marker und Technologien. Pathologe. 2015;36(2):154–63. CrossRef Warth A, Endris V, Kriegsmann M, Stenzinger A, Penzel R, Pfarr N, Weichert W. Molekulardiagnostik des nichtkleinzelligen Lungenkarzinoms. Neue Marker und Technologien. Pathologe. 2015;36(2):154–63. CrossRef
6.
Zurück zum Zitat Castellanos E, Horn L. Generations of epidermal growth factor receptor Tyrosine Kinase inhibitors: perils and progress. Curr Treat Options Oncol. 2015;16:51. CrossRef Castellanos E, Horn L. Generations of epidermal growth factor receptor Tyrosine Kinase inhibitors: perils and progress. Curr Treat Options Oncol. 2015;16:51. CrossRef
7.
Zurück zum Zitat Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34. CrossRef Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34. CrossRef
8.
Zurück zum Zitat Levy B, Rao P, Becker D, Becker K. Attacking a moving target: understanding resistance and managing progression in EGFR-positive lung cancer patients treated with Tyrosine Kinase inhibitors. Oncology. 2016;30(7):601–12. PubMed Levy B, Rao P, Becker D, Becker K. Attacking a moving target: understanding resistance and managing progression in EGFR-positive lung cancer patients treated with Tyrosine Kinase inhibitors. Oncology. 2016;30(7):601–12. PubMed
9.
Zurück zum Zitat Huang L, Fu L. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B. 2015;5(5):390–401. CrossRef Huang L, Fu L. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B. 2015;5(5):390–401. CrossRef
10.
Zurück zum Zitat Lo P, Dahlberg S, Nishino M, Johnson B, Sequist L, Jackman D, et al. Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer. Cancer. 2015;121(15):2570–7. CrossRef Lo P, Dahlberg S, Nishino M, Johnson B, Sequist L, Jackman D, et al. Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer. Cancer. 2015;121(15):2570–7. CrossRef
11.
Zurück zum Zitat Weickhardt A, Scheier B, Burke J, Gan G, Lu X, Bunn P, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012;7(12):1807–14. CrossRef Weickhardt A, Scheier B, Burke J, Gan G, Lu X, Bunn P, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012;7(12):1807–14. CrossRef
12.
Zurück zum Zitat Yu H, Sima C, Huang J, Solomon S, Rimner A, Paik P, et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2013;8(3):346–51. CrossRef Yu H, Sima C, Huang J, Solomon S, Rimner A, Paik P, et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2013;8(3):346–51. CrossRef
13.
Zurück zum Zitat Auliac J, Fournier C, Audigier V, Perol M, Bizieux A, Vinas F, et al. Impact of continuing first-line EGFR Tyrosine Kinase inhibitor therapy beyond RECIST disease progression in patients with advanced EGFR-mutated non-small-cell lung cancer (NSCLC): retrospective GFPC 04-13 study. Target Oncol. 2016;11(2):167–74. CrossRef Auliac J, Fournier C, Audigier V, Perol M, Bizieux A, Vinas F, et al. Impact of continuing first-line EGFR Tyrosine Kinase inhibitor therapy beyond RECIST disease progression in patients with advanced EGFR-mutated non-small-cell lung cancer (NSCLC): retrospective GFPC 04-13 study. Target Oncol. 2016;11(2):167–74. CrossRef
14.
Zurück zum Zitat Goldberg S, Oxnard G, Digumarthy S, Muzikansky A, Jackman D, Lennes I, Sequist V. Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors. Oncologist. 2013;18(11):1214–20. CrossRef Goldberg S, Oxnard G, Digumarthy S, Muzikansky A, Jackman D, Lennes I, Sequist V. Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors. Oncologist. 2013;18(11):1214–20. CrossRef
15.
Zurück zum Zitat Soria J, Wu Y, Nakagawa K, Kim S, Yang J, Ahn M, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015;16(8):990–8. CrossRef Soria J, Wu Y, Nakagawa K, Kim S, Yang J, Ahn M, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015;16(8):990–8. CrossRef
16.
Zurück zum Zitat Scagliotti G, von Pawel J, Novello S, Ramlau R, Favaretto A, Barlesi F, et al. Phase III multinational, randomized, double-blind, placebo-controlled study of Tivantinib (ARQ 197) plus Erlotinib versus Erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015;33(24):2667–74. CrossRef Scagliotti G, von Pawel J, Novello S, Ramlau R, Favaretto A, Barlesi F, et al. Phase III multinational, randomized, double-blind, placebo-controlled study of Tivantinib (ARQ 197) plus Erlotinib versus Erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015;33(24):2667–74. CrossRef
17.
Zurück zum Zitat Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N, et al. Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39. CrossRef Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N, et al. Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39. CrossRef
18.
Zurück zum Zitat Masago K, Fujita S, Muraki M, Hata A, Okuda C, Otsuka K, et al. Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations. BMC Cancer. 2015;15:908. CrossRef Masago K, Fujita S, Muraki M, Hata A, Okuda C, Otsuka K, et al. Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations. BMC Cancer. 2015;15:908. CrossRef
19.
Zurück zum Zitat Jänne P, Yang J, Kim D, Planchard D, Ohe Y, Ramalingam S, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689–99. CrossRef Jänne P, Yang J, Kim D, Planchard D, Ohe Y, Ramalingam S, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689–99. CrossRef
20.
Zurück zum Zitat Sequist L, Soria J, Goldman J, Wakelee H, Gadgeel S, Varga A, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015;372(18):1700–9. CrossRef Sequist L, Soria J, Goldman J, Wakelee H, Gadgeel S, Varga A, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015;372(18):1700–9. CrossRef
21.
Zurück zum Zitat Costa D, Kobayashi S. Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M. Transl Lung Cancer Res. 2015;4(6):809–15. PubMedPubMedCentral Costa D, Kobayashi S. Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M. Transl Lung Cancer Res. 2015;4(6):809–15. PubMedPubMedCentral
Metadaten
Titel
Therapy for EGFR tyrosine kinase inhibitor-resistant NSCLC with a focus on the T790M-resistant mutation
verfasst von
MD, Priv. Doz. August Zabernigg
Publikationsdatum
01.12.2016
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2016
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-016-0288-y